

OBJECTIVES				
Review	Provide	Discuss		
Review the burden of Healthcare- associated infections (HAI)s	Provide an overview of the evolution of Infection Prevention/Control	Discuss core components of an infection prevention program		
		SPICE		

CDC 2022 NATIONAL AND STATE HAI PROGRESS REPORT

(11/23)

- The 2022 annual National and State Healthcare-Associated Infections (HAI) Progress Report provides a summary of select HAIs across four healthcare settings: acute care hospitals (ACHs), critical access hospitals (CAHs), inpatient rehabilitation facilities (IRFs) and long-term acute care hospitals (LTACHs).
 - Central line-associated bloodstream infections (CLABSIs)- 9%
 - Catheter-associated urinary tract infections (CAUTIs))-12%
 - Ventilator-associated events (VAEs)-19%
 - Surgical site infections (SSIs)- no significant change
 - Methicillin-resistant Staphylococcus aureus (MRSA) bloodstream events-16%
 - Clostridioides difficile (C. difficile) events- 3%



Metric	# Observed Infections	# Predicted infections	Compare to National Experience
CLABSI	729	653.68	WORSE
CAUTI	572	705.71	BETTER
Abd Hysterectomy SSI)	66	70.48	SAME
Colon (SSI)	309	310.73	SAME
MRSA LabID	370	417.95	BETTER
C diff LabID	1,235	3,090.2	BETTER





OBJECTIVES				
Review	Provide	Discuss		
Review the burden of Healthcare- associated infections (HAI)s	Provide an overview of the evolution of Infection Prevention/Control	Discuss core components of an infection prevention program		

"The field of infection prevention emerged from the results of the Study of the Efficacy of Nosocomial Infection Control (SENIC), which demonstrated that strategies such as surveillance and feedback led to sizeable decreases in hospital-acquired infections"

SPICE

UpToDate: Infection prevention: General principles Authors: Deverick JAnderson, MD, MPH; N Deborah Friedman, MPH, MBBS, FRACP, MD Section Editor: Daniel J Sexton, MD Deputy Editor: Meg Sullivan, MD











OBJECTIVES		
Review	Provide	Discuss
Review the burden of Healthcare- associated infections (HAI)s	Provide an overview of the evolution of Infection Prevention/Control	Discuss core components of an infection prevention program





























EDUCATION AND TRAINING OF HEALTHCARE PERSONNEL ON INFECTION PREVENTION

- Training should be adapted to reflect the diversity of the workforce and the type of facility, and tailored to meet the needs of each category of healthcare personnel trained
 - Job-specific, infection prevention education and training
 - Processes to ensure that personnel are competent
 - Written policies and procedures
 - Training before duties can be performed and at least annually
 - Additional training to recognized lapses in adherence

















Immunize	Establish	Adhere
Immunize against vaccine-preventable diseases • Hepatitis B • Influenza • MMR • Varicella • Tetanus, diphtheria, pertussis • COVID-19	Establish sick leave policies that encourage: • Healthcare personnel to stay home when they are ill • Reporting of signs, symptoms, and diagnosed illnesses that may represent a risk to their patients and coworkers	Adhere to federal and state standards and directives applicable to protecting healthcare workers against transmission of infectious agents











	Likelihood	Severity	Preparedness	Risk Score
Facility Related	1(low)- 5(high)	1(low)- 5(high)	1(low)-5(high)	(Likelihood X Severity)/ Preparedness
Influenza like illness				
Symptomatic UTI	5	5	1	25
Cellulitis/SST Infection				
C difficile				
 Example: Symptomatic UTI:	Als in <u>2019</u> e documented			





















TARGETED SURVEILLANCE		
Pros	Cons	
Risk-adjusted rates	May miss some infections	
Can measure trends and make comparisons	Limited information on endemic rates	
More efficient use of resources		
Can target potential problems		
Identify performance improvement opportunities		
Can evaluate effectiveness of prevention activities		
	SPIC	











Characteristic	Semiautomated	Fully Automated
Clinical data	Accurate, reliable (clinical) data	Accurate, reliable (clinical) data
Definition	Standardized; not specifically adapted to automation	Standardized; adapted to auto- mation (healthcare-associ- ated infection metric)
Final ascertainment	Chart review required; some room for clinical judgment	No chart review; subjective interpretation impossible
Performance characteristics	High sensitivity, high negative predictive value	High specificity, high positive predictive value
Features	Clinical acceptance; room for adaptation within hospitals remains	Possible reduction in clinician buy-in; standardization, trade-off with sensitivity, specificity

	Surveillance Definitions	Clinical Diagnosis
Purpose	Identify trends <u>within a</u> <u>population</u> for prevention	Identify disease in, and treatment for, <u>individual patients</u>
Components	Limited predetermined data elements	All diagnostic information available
Clinical Judgment	Excluded if possible	Valued
determinations w	mes clinical judgm ill not match. Surv epidemiologic sur	eillance determina













ABISP	NHSN Organism Category	NHSN Display Name	-I SNOMED Preferred Term	* SNOMED Code *
	ALL/MS/JII	Abiotrophia	Abiotrophia	115161005
GRADI*2	ALL/MBI/UTI	Abiotrophia adiacens	Granulicatella adiacens	113713009
GRADJ*3	ALL/ME/M	Abiotrophia adjacens	Granulicatella adiacens	113713009
STRDF	ALL/MBI/UTI	Abiotrophia defectiva	Abiotrophia defectiva	113714003
GRANELEG*1	ALL/MB/UR	Abiotrophia elegans	Granulicatella elegans	115944008
ACANT	ALL	Acanthamoeba	Acanthamoeba	50875003
ACHOSP	ALL/IT	Acholeplasma	Acholeplasma	84858009
ACHOLAID	ALL/UT	Acholeplasma laidlawii	Acholeplasma laidlawii	89082003
ACHOOCUL	ALL/UT	Acholeplasma oculi	Acholeplasma oculi	86450009
ACHSP	ALL/	Achromobacter	Achromobacter	91620006
ACHDENI	ALL/UT	Achromobacter denitrificans	Achromobacter denitrificans	413414001
ACHPIEC	ALL/UT	Achromobacter piechaudii	Achromobacter piechaudii	413420000
ACHRUHL	ALL/UT	Achromobacter ruhlandii	Achromobacter ruhlandii	413421001
ALCXYL	ALL/JIT	Achromobacter xylosoxidans	Achromobacter xylosoxidans	413424009
ACHXYL	ALL/UT	Achromobacter xylosoxidans xylosoxidans	Achromobacter xylosoxidans xylosoxidans	423897003
ACISP	ALL/IM	Acidaminococcus	Acidaminococcus	28207003
ACIFE	ALL/UD	Acidaminococcus fermentans	Acidaminococcus fermentans	63005002
AFB	ALL/UTI	Acid-fast bacillus	Acid-fast bacillus	243365003
ACIDSP	ALL/UT	Acidovorax	Acidovorax	115153000
ACDEL	ALL/UTI	Acidovorax delafieldii	Acidovorax delafieldii	113685003
ACIDEACI	ALL/UT	Acidovorax facilis	Acidovorax facilis	113686002
ACIDTEMP	ALL/UT	Acidovorax temperans	Acidovorax temperans	113687006
ACS	ALL/UTT	Acinetobacter	Acinetobacter	7757008
ACBA	ALL/UT	Acinetobacter baumannii	Acinetobacter baumannli	91288006
ACICBA	ALL/UT	Acinetobacter calcoaceticus	Acinetobacter calcoaceticus	82550008
ACCA	ALL/UTI	Acinetobacter calcoaceticus-baumannii complex	Acinetobacter calcoaceticus-Acinetobacter baumannii complex	113376007










/3









<section-header><section-header><section-header><section-header><section-header><text><text><text>















Hospital Day	RIT	SUTI Criterion	
1		<u>†</u>	
2			
3 DOE	1	Fever >38.0°C	
4	2	Urine culture + >10 ⁵ cfu/ml <i>E. Coli</i>	
5	3	<u>†</u>	
6	4		
7	5	↓	
8	6		
9	7		
10	8		
11	9		
12	10		
13	11		
14	12		
15	13		
16	14		E



Hospital	BSI	RIT	Infection Window	Infection Window	RIT
Day					
1					
2					
3			Fever > 38.0° C		
4			Urine culture + >100,000 cfu/ml K. pneumonia		
5					
6					
7					
8					
9					
10			Blood Culture; K. pneumonia/Yeast		
11					
12					
13					
14					
15					
16					



Hospital Day	BSI	RIT	Infection Window	Infection Window	RIT
1					
2					
³ DOE			Fever > 38.0° C		
4			Urine culture + >100,000 cfu/ml K. pneumonia		
5					
6					
7					
8					
9					
¹⁰ DOE			Blood Culture; K. pneumonia/Yeast		
11					
12					
13					
14					
15					
16			UTI & Secondary BSI with K. pneumo	onia Primary BSI with Yeast	















"Good surveillance does not necessarily ensure the making of the right decision, but it reduces the chances of wrong ones."

Alexander D. Langmuir



